Recovery from botulinum neurotoxin poisoning in vivo

Neuroscience

Volumn 139, Issue 2, 2006, Pages 629-637

  Keller, J E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

botulinum neurotoxin; botulism; paralysis; potency assay; recovery

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; MALE; MOUSE; MUSCLE FUNCTION; NEUROTOXICITY; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; RUNNING; SEROTYPE; STATISTICAL ANALYSIS;

ANIMALS; ANTIOXIDANTS; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; BOTULISM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED BALB C; NEUROTOXINS; RECOVERY OF FUNCTION; RUNNING; TIME FACTORS;

EID: 33645861959     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2005.12.029     Document Type: Article

References (56)

1. Adler M., Capacio B., and Deshpande S.S. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps. Toxicon 38 (2000) 1381-1388
2. Adler M., Keller J.E., Sheridan R.E., and Deshpande S.S. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon 39 (2001) 233-243
3. Allen D.L., Harrison B.C., Maass A., Bell M.L., Byrnes W.C., and Leinwand L.A. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J Appl Physiol 90 (2001) 1900-1908
4. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39 (2001) 1815-1820
5. Ball A.P., Hopkinson R.B., Farrell I.D., Hutchison J.G., Paul R., Watson R.D., Page A.J., Parker R.G., Edwards C.W., Snow M., Scott D.K., Leone-Ganado A., Hastings A., Ghosh A.C., and Gilbert R.J. Human botulism caused by Clostridium botulinum type E. the Birmingham outbreak. Q J Med 48 (1979) 473-491
6. Blasi J., Chapman E.R., Link E., Binz T., Yamasaki S., De Camilli P., Sudhof T.C., Niemann H., and Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365 (1993) 160-163
7. Boquet P., and Duflot E. Tetanus toxin fragment forms channels in lipid vesicles at low pH. Proc Natl Acad Sci U S A 79 (1982) 7614-7618
8. Brashear A., Lew M.F., Dykstra D.D., Comella C.L., Factor S.A., Rodnitzky R.L., Trosch R., Singer C., Brin M.F., Murray J.J., Wallace J.D., Willmer-Hulme A., and Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53 (1999) 1439-1446
9. Brin M.F., Lew M.F., Adler C.H., Comella C.L., Factor S.A., Jankovic J., O'Brien C., Murray J.J., Wallace J.D., Willmer-Hulme A., and Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53 (1999) 1431-1438
10. Brown M.C., Holland R.L., and Ironton R. Nodal and terminal sprouting from motor nerves in fast and slow muscles of the mouse. J Physiol 306 (1980) 493-510
11. Centers for Disease Control and Prevention. Botulism in the United States, 1899-1996. Handbook for epidemiologists, clinicians, and laboratory workers (1998), Centers for Disease Control and Prevention, Atlanta, GA
12. Coffield J.A., Considine R.V., and Simpson L.L. Clostridial neurotoxins in the age of molecular medicine. Trends Microbiol 2 (1994) 67-69 discussion 69-72
13. Colebatch J.G., Wolff A.H., Gilbert R.J., Mathias C.J., Smith S.E., Hirsch N., and Wiles C.M. Slow recovery from severe foodborne botulism. Lancet 2 (1989) 1216-1217
14. Costantin L., Bozzi Y., Richichi C., Viegi A., Antonucci F., Funicello M., Gobbi M., Mennini T., Rossetto O., Montecucco C., Maffei L., Vezzani A., and Caleo M. Antiepileptic effects of botulinum neurotoxin E. J Neurosci 25 (2005) 1943-1951
15. Cull-Candy S.G., Lundh H., and Thesleff S. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol 260 (1976) 177-203
16. Duchen L.W. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci 14 (1971) 47-60
17. Duncan R.M., and Jensen W.L. A relationship between avian carcasses and living invertebrates in the epizootiology of avian botulism. J Wildl Dis 12 (1976) 116-126
18. Eleopra R., Tugnoli V., Rossetto O., De Grandis D., and Montecucco C. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256 (1998) 135-138
19. Fasshauer D., Eliason W.K., Brunger A.T., and Jahn R. Identification of a minimal core of the synaptic SNARE complex sufficient for reversible assembly and disassembly. Biochemistry 37 (1998) 10354-10362
20. Foran P.G., Mohammed N., Lisk G.O., Nagwaney S., Lawrence G.W., Johnson E., Smith L., Aoki K.R., and Dolly J.O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 278 (2003) 1363-1371
21. Habermann E., and Dreyer F. Clostridial neurotoxins. handling and action at the cellular and molecular level. Curr Top Microbiol Immunol 129 (1986) 93-179
22. Hallett M. One man's poison. clinical applications of botulinum toxin. N Engl J Med 341 (1999) 118-120
23. Hayashi T., McMahon H., Yamasaki S., Binz T., Hata Y., Sudhof T.C., and Niemann H. Synaptic vesicle membrane fusion complex. action of clostridial neurotoxins on assembly. EMBO J 13 (1994) 5051-5061
24. Hubalek Z., Pellantova J., Hudec K., Halouzka J., Chytil J., Machacek P., Sebela M., and Kubicek F. [Botulism in birds living in an aquatic environment in Nove Mlyny in the Breclav District]. Vet Med (Praha) 36 (1991) 57-63
25. Hughes J.M., Blumenthal J.R., Merson M.H., Lombard G.L., Dowell Jr. V.R., and Gangarosa E.J. Clinical features of types A and B food-borne botulism. Ann Intern Med 95 (1981) 442-445
26. Irani B.G., Xiang Z., Moore M.C., Mandel R.J., and Haskell-Luevano C. Voluntary exercise delays monogenetic obesity and overcomes reproductive dysfunction of the melanocortin-4 receptor knockout mouse. Biochem Biophys Res Commun 326 (2005) 638-644
27. Jahn R., and Niemann H. Molecular mechanisms of clostridial neurotoxins. Ann N Y Acad Sci 733 (1994) 245-255
28. Jankovic J., and Brin M.F. Therapeutic uses of botulinum toxin. N Engl J Med 324 (1991) 1186-1194
29. Jurasinski C.V., Lieth E., Dang Do A.N., and Schengrund C.L. Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 39 (2001) 1309-1315
30. Keller J.E., Neale E.A., Oyler G., and Adler M. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456 (1999) 137-142
31. Koenig M.G., Spickard A., Cardella M.A., and Rogers D.E. Clinical and laboratory observations on type E botulism in man. Medicine (Baltimore) 43 (1964) 517-545
32. Konhilas J.P., Maass A.H., Luckey S.W., Stauffer B.L., Olson E.N., and Leinwand L.A. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol 287 (2004) H2768-H2776
33. Koriazova L.K., and Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10 (2003) 13-18
34. Lightfoot J.T., Turner M.J., Daves M., Vordermark A., and Kleeberger S.R. Genetic influence on daily wheel running activity level. Physiol Genomics 19 (2004) 270-276
35. McMahon H.T., and Sudhof T.C. Synaptic core complex of synaptobrevin, syntaxin, and SNAP25 forms high affinity alpha-SNAP binding site. J Biol Chem 270 (1995) 2213-2217
36. Meunier F.A., Lisk G., Sesardic D., and Dolly J.O. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins. the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 22 (2003) 454-466
37. Montecucco C., and Schiavo G. Tetanus and botulism neurotoxins. a new group of zinc proteases. Trends Biochem Sci 18 (1993) 324-327
38. Ohishi I., and Sakaguchi G. Activation of botulinum toxins in the absence of nicking. Infect Immunol 17 (1977) 402-407
39. Pevsner J., and Scheller R.H. Mechanisms of vesicle docking and fusion. insights from the nervous system. Curr Opin Cell Biol 6 (1994) 555-560
40. Polak R.L., Sellin L.C., and Thesleff S. Acetylcholine content and release in denervated or botulinum poisoned rat skeletal muscle. J Physiol 319 (1981) 253-259
41. Schantz E.J., and Johnson E.A. Dose standardisation of botulinum toxin. Lancet 335 (1990) 421
42. Schiavo G., Matteoli M., and Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 80 (2000) 717-766
43. Schiavo G., Rossetto O., Santucci A., DasGupta B.R., and Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem 267 (1992) 23479-23483
44. Sellin L.C. The action of botulinum toxin at the neuromuscular junction. Med Biol 59 (1981) 11-20
45. Sellin L.C., Kauffman J.A., and Dasgupta B.R. Comparison of the effects of botulinum neurotoxin types A and E at the rat neuromuscular junction. Med Biol 61 (1983) 120-125
46. Sellin L.C., Thesleff S., and Dasgupta B.R. Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction. Acta Physiol Scand 119 (1983) 127-133
47. Sellin L.C., and Thesleff S. Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction. J Physiol 317 (1981) 487-495
48. Shapiro R.L., Hatheway C., and Swerdlow D.L. Botulism in the United States. a clinical and epidemiologic review. Ann Intern Med 129 (1998) 221-228
49. Sheridan R.E., Smith T.J., and Adler M. Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon 45 (2005) 377-382
50. Simpson L.L. The interaction between divalent cations and botulinum toxin type A in the paralysis of the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology 12 (1973) 165-176
51. Simpson L.L. Pharmacological studies on the subcellular site of action of botulinum toxin type A. J Pharmacol Exp Ther 206 (1978) 661-669
52. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44 (2004) 167-193
53. Sloop R.R., Cole B.A., and Escutin R.O. Human response to botulinum toxin injection. type B compared with type A. Neurology 49 (1997) 189-194
54. Tucker N., Sobel J., Maslanka S.E., Griffin P.M., and Tauxe R.V. Surveillance for botulism. summary of 2001 data (2002) 1-11. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/botulism_a.htm Centers for Disease Control and Prevention web site. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/botulism_a.htm
55. Whittaker R.L., Gilbertson R.B., and Garrett Jr. A.S. Botulism, type E. report of eight simultaneous cases. Ann Intern Med 61 (1964) 448-454
56. Woodruff B.A., Griffin P.M., McCroskey L.M., Smart J.F., Wainwright R.B., Bryant R.G., Hutwagner L.C., and Hatheway C.L. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis 166 (1992) 1281-1286